Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zentek ( (TSE:ZEN) ) has issued an announcement.
On April 14, 2026, Zentek said its subsidiary Triera Biosciences completed a Government of Canada Innovative Solutions Canada contract to develop an aptamer-based asset targeting the highly pathogenic avian influenza H5N1 strain. Triera reported selecting a suitable aptamer in about seven weeks, underscoring the platform’s speed versus conventional antibody approaches and supporting its broader infectious disease technology credentials.
Building on this work, Triera has signed an Ontario Centres of Innovation Collaborate 2 Commercialize agreement to co-fund a roughly $300,000 program with Zentek to advance proprietary seasonal influenza treatment candidates. Working with McMaster University labs, the project will extend the aptamer platform to common seasonal influenza A subtypes H1N1 and H3N2, with planned candidate optimization, expanded strain coverage, early toxicology and PK/PD work, reinforcing Triera’s push toward clinically viable flu therapeutics.
Spark’s Take on ZEN Stock
According to Spark, TipRanks’ AI Analyst, ZEN is a Neutral.
The score is primarily held back by weak financial performance—limited revenue scale, negative margins, and continued cash burn—only partially offset by a low-leverage balance sheet. Technicals add pressure as the stock trades below key moving averages with a negative MACD, while valuation signals are inconclusive due to negative earnings and no dividend data.
To see Spark’s full report on ZEN stock, click here.
More about Zentek
Zentek Ltd. is a Canadian intellectual property development and commercialization company focused on graphene-enabled and advanced material technologies across clean air, next-generation materials, and critical minerals. Its core platforms include Albany Graphite, the ZenGUARD™ filtration technology, and its Triera biosciences subsidiary, which develops aptamer-based molecular recognition and therapeutic solutions.
Average Trading Volume: 56,162
Technical Sentiment Signal: Sell
Current Market Cap: C$78.51M
See more insights into ZEN stock on TipRanks’ Stock Analysis page.